Skip to main content
OpenTrials
Completed

NCT Number: NCT00455351

Vorinostat and Palliative Radiotherapy

Phase I study. Side-effects when combined with standard palliative radiotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pelvic Cancer Neoplasms Neoplasms by Site Pelvic Neoplasms Radiotherapy

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

The Norwegian Radium Hospital

Oslo, NO-0310, Norway

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pelvic malignancy
  • Palliative radiation treatment planed
  • ECOG <3
  • Age>18 years

Exclusion criteria

  • Previous pelvic radiotherapy
  • Uncontrolled diarrhea
  • Insulin-dependent diabetes mellitus
  • BMI<18.5

Treatment and study plan

Vorinostat

Drug

Increasing dosing, phase I

Primary outcomes

  1. DLT

    Time frame: continously

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Registry information

Official study title

Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.

Acronym: PRAVO

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Apr 3, 2007
Registry last updated
May 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.